Request for Information (RFI): Inviting Feedback on the NIH Office of Disease Prevention Strategic Plan for Fiscal Years 2024-2028, 23447-23448 [2023-08044]

Download as PDF lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 88, No. 73 / Monday, April 17, 2023 / Notices The meeting can be accessed from the NIH Videocast https://videocast. nih.gov/ and CCRHB https://ccrhb. od.nih.gov/meetings.html websites. DEPARTMENT OF HEALTH AND HUMAN SERVICES Name of Committee: NIH Clinical Center Research Hospital Board. Date: June 16, 2023. Time: 9:30 a.m. to 1:00 p.m. Agenda: NIH and Clinical Center (CC) Leadership Announcements, CC CEO Update of Recent Activities and Organizational Priorities, Status Report on Key CC Strategic Plan Initiatives, and Other Business of the Clinical Center Research Hospital Board (CCRHB). Place: National Institutes of Health, Building 31, Conference Room 6C02 A & B, 9000 Rockville Pike, Bethesda, MD 20892. Contact Persons: Patricia Piringer, RN, MSN (C), National Institutes of Health Clinical Center, 10 Center Drive, Bethesda, MD 20892, ppiringer@cc.nih.gov, (301) 402– 2435, (202) 460–7542 (direct). Natascha Pointer, Management Analyst, Executive Assistant to Dr. Gilman, Office of the Chief Executive Officer, National Institutes of Health Clinical Center, 10 Center Drive, Bethesda, MD 20892, npointer@ cc.nih.gov, (301) 496–4114, (301) 402–2434 (direct). Any interested person may file written comments with the committee by forwarding the statement to the Contact Person(s) listed on this notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. Meeting information is also available on the CCRHB website: https:// www.ccrhb.od.nih.gov/ where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) National Center for Advancing Translational Sciences; Notice of Meeting National Institutes of Health Dated: April 12, 2023. Patricia B. Hansberger, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2023–08071 Filed 4–14–23; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 16:57 Apr 14, 2023 Jkt 259001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Center for Advancing Translational Sciences Advisory Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend as well as those who need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting website (https://videocast.nih.gov/). The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Advancing Translational Sciences Advisory Council. Date: May 25, 2023. Closed: 11:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Advancing Translational Sciences, National Institutes of Health, Building B, Room 377, 9800 Medical Center Drive, Rockville, MD 20850. Open: 1:00 p.m. to 6:00 p.m. Agenda: Report from the Center Director, 2024 NCATS Strategic Plan, Program Updates (2). Place: National Center for Advancing Translational Sciences, National Institutes of Health, Building B, Room 377, 9800 Medical Center Drive, Rockville, MD 20850. Contact Person: Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, 1 Democracy Plaza, Room 1072, Bethesda, MD 20892, 301–435–0809, anna.ramseyewing@ nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice no later than 15 days after the meeting at NCATSCouncilInput@ mail.nih.gov. The statement should include the name, address, telephone number and PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 23447 when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Dated: April 12, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–08074 Filed 4–14–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information (RFI): Inviting Feedback on the NIH Office of Disease Prevention Strategic Plan for Fiscal Years 2024–2028 AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Institutes of Health (NIH), Office of the Director, Office of Disease Prevention (ODP) is requesting public comment on its draft strategic plan for Fiscal Years 2024– 2028 (FY24–28), Prevention Research: Creating a Healthier Future for All. ODP invites feedback on its proposed priorities from prevention researchers in academia and industry, health care providers, patient advocacy organizations, community-based organizations, health service organizations, scientific or professional organizations, trainees and early-stage investigators, federal agencies, those employed by NIH or at institutions receiving NIH support, and the general public. Organizations are strongly encouraged to submit a single response that reflects the views of the organization and membership as a whole. SUMMARY: ODP’s RFI is open for public comment through May 22, 2023. Responses must be received by 11:59 DATES: E:\FR\FM\17APN1.SGM 17APN1 23448 Federal Register / Vol. 88, No. 73 / Monday, April 17, 2023 / Notices p.m. ET on May 22, 2023, to ensure consideration. All comments must be submitted electronically on the submission website available at https:// rfi.grants.nih.gov/?s=63d9edb46e8d6 ea804099132. ADDRESSES: lotter on DSK11XQN23PROD with NOTICES1 FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to Wilma Peterman Cross; ODP, NIH; Phone: 301– 827–5561; email: prevention@nih.gov. SUPPLEMENTARY INFORMATION: This notice is in accordance with the 21st Century Cures Act, wherein NIH institutes are required to regularly update their strategic plans. ODP was established in the NIH Office of the Director in 1986. In accordance with 42 U.S.C. 282(f) of the Public Health Service Act, as amended, the mission of ODP is to improve public health by increasing the scope, quality, dissemination, and impact of prevention research supported by NIH. ODP fulfills this mission by providing leadership for the development, coordination, and implementation of prevention research in collaboration with NIH Institutes, Centers, and Offices, and other partners. The office has made considerable progress (https://prevention.nih.gov/ about-odp/strategic-plan/spotlightprogress) on the priorities identified in our strategic plan for FY19–23 (https:// prevention.nih.gov/about-odp/strategicplan-2019-2023), and ODP remains committed to playing an integral role in enhancing prevention-related activities across NIH as well as serving as a partner with its federal colleagues. Input received from this RFI will inform the development of the final ODP FY24–28 Strategic Plan, Prevention Research: Creating a Healthier Future for All, which will outline activities coordinated by the office to assess, facilitate, and stimulate research in disease prevention, and disseminate the results of this research to improve public health. The definition of prevention research that ODP uses to guide its work and decision-making covers research designed to identify and assess risk, and to develop and test interventions to prevent or reduce harmful behaviors and exposures, disease onset, or disease progression. Prevention research spans all diseases and conditions, populations, and phases of life. Specifically, ODP focuses on primary and secondary prevention research in humans. • Primary prevention research includes research designed to promote health; identify risk factors for developing a new health condition (e.g., VerDate Sep<11>2014 16:57 Apr 14, 2023 Jkt 259001 disease, disorder, injury); and prevent the onset of a new health condition. • Secondary prevention research includes research designed to identify risk factors for the progression or recurrence of a health condition, and to detect and prevent progression of an asymptomatic or early-stage condition. Prevention research targets biology, behaviors, factors in the social and physical environments, and health services. It also informs and evaluates health-related policies and regulations. Examples of prevention research include studies that: • Identify and assess risk and protective factors • Screen and identify individuals and groups at risk • Develop and evaluate interventions to reduce risk • Translate, implement, and disseminate effective preventive interventions into practice • Develop methods to support prevention research ODP’s strategic priorities are intentionally not specific to any given disease because prevention research is relevant to all health conditions and to promoting health in everyone; NIH’s Institutes and Centers serve as the best place for disease-specific or conditionspecific research. As a coordinating office in the Division of Program Coordination, Planning, and Strategic Initiatives within the NIH Office of the Director, ODP is best positioned to identify important research gaps, fostering collaborations across NIH and with federal partners, and promoting rigorous research practices. Request for Information ODP is seeking feedback on these draft strategic priorities: 1. Systematically monitor NIH investments in prevention research and the progress and results of that research. 2. Identify prevention research areas for investment or expanded effort by NIH. 3. Promote the use of the best available methods in prevention research and support the development of better methods. 4. Promote collaborative prevention research projects and facilitate coordination of such projects across NIH and with other public and private entities. 5. Advance tobacco regulatory and prevention science. 6. Promote and coordinate prevention research that addresses health disparities. 7. Improve the availability and visibility of information about PO 00000 Frm 00059 Fmt 4703 Sfmt 9990 prevention research, inform diverse audiences about the scope and impact of disease prevention research, and engage with ODP’s partners to enhance and support ODP’s mission. ODP is also seeking feedback on areas where targeted efforts by ODP could help accelerate prevention research. How To Submit a Response All responses to this RFI must be submitted electronically on the RFI submission website at https:// rfi.grants.nih.gov/?s=63d9edb46e8d6 ea804099132. Responses must be received by May 22, 2023, at 11:59 p.m. ET. You will see an electronic confirmation acknowledging receipt of your response. Responses to this RFI are voluntary and may be submitted anonymously. You may voluntarily include your name and contact information with your response. If you choose to provide NIH with this information, NIH will not share your name and contact information outside of NIH unless required by law. Other than your name and contact information, please do not include any personally identifiable information or any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The government will use the information submitted in response to this RFI at its discretion. Other than your name and contact information, the government reserves the right to use any submitted information on public websites; in reports; in summaries of the state of the science; in any possible resultant solicitation(s), grant(s), or cooperative agreement(s); or in the development of future funding opportunities. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the government to provide support for any ideas identified in response to it. Please note that the government will not pay for the preparation of any information submitted or for use of that information. Dated: April 10, 2023. Tara A. Schwetz, Acting Principal Deputy Director, National Institutes of Health. [FR Doc. 2023–08044 Filed 4–14–23; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\17APN1.SGM 17APN1

Agencies

[Federal Register Volume 88, Number 73 (Monday, April 17, 2023)]
[Notices]
[Pages 23447-23448]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08044]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Request for Information (RFI): Inviting Feedback on the NIH 
Office of Disease Prevention Strategic Plan for Fiscal Years 2024-2028

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health (NIH), Office of the 
Director, Office of Disease Prevention (ODP) is requesting public 
comment on its draft strategic plan for Fiscal Years 2024-2028 (FY24-
28), Prevention Research: Creating a Healthier Future for All. ODP 
invites feedback on its proposed priorities from prevention researchers 
in academia and industry, health care providers, patient advocacy 
organizations, community-based organizations, health service 
organizations, scientific or professional organizations, trainees and 
early-stage investigators, federal agencies, those employed by NIH or 
at institutions receiving NIH support, and the general public. 
Organizations are strongly encouraged to submit a single response that 
reflects the views of the organization and membership as a whole.

DATES: ODP's RFI is open for public comment through May 22, 2023. 
Responses must be received by 11:59

[[Page 23448]]

p.m. ET on May 22, 2023, to ensure consideration.

ADDRESSES: All comments must be submitted electronically on the 
submission website available at https://rfi.grants.nih.gov/?s=63d9edb46e8d6ea804099132.

FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to Wilma 
Peterman Cross; ODP, NIH; Phone: 301-827-5561; email: 
[email protected].

SUPPLEMENTARY INFORMATION: This notice is in accordance with the 21st 
Century Cures Act, wherein NIH institutes are required to regularly 
update their strategic plans. ODP was established in the NIH Office of 
the Director in 1986. In accordance with 42 U.S.C. 282(f) of the Public 
Health Service Act, as amended, the mission of ODP is to improve public 
health by increasing the scope, quality, dissemination, and impact of 
prevention research supported by NIH. ODP fulfills this mission by 
providing leadership for the development, coordination, and 
implementation of prevention research in collaboration with NIH 
Institutes, Centers, and Offices, and other partners. The office has 
made considerable progress (https://prevention.nih.gov/about-odp/strategic-plan/spotlight-progress) on the priorities identified in our 
strategic plan for FY19-23 (https://prevention.nih.gov/about-odp/strategic-plan-2019-2023), and ODP remains committed to playing an 
integral role in enhancing prevention-related activities across NIH as 
well as serving as a partner with its federal colleagues.
    Input received from this RFI will inform the development of the 
final ODP FY24-28 Strategic Plan, Prevention Research: Creating a 
Healthier Future for All, which will outline activities coordinated by 
the office to assess, facilitate, and stimulate research in disease 
prevention, and disseminate the results of this research to improve 
public health.
    The definition of prevention research that ODP uses to guide its 
work and decision-making covers research designed to identify and 
assess risk, and to develop and test interventions to prevent or reduce 
harmful behaviors and exposures, disease onset, or disease progression. 
Prevention research spans all diseases and conditions, populations, and 
phases of life.
    Specifically, ODP focuses on primary and secondary prevention 
research in humans.
     Primary prevention research includes research designed to 
promote health; identify risk factors for developing a new health 
condition (e.g., disease, disorder, injury); and prevent the onset of a 
new health condition.
     Secondary prevention research includes research designed 
to identify risk factors for the progression or recurrence of a health 
condition, and to detect and prevent progression of an asymptomatic or 
early-stage condition.
    Prevention research targets biology, behaviors, factors in the 
social and physical environments, and health services. It also informs 
and evaluates health-related policies and regulations. Examples of 
prevention research include studies that:

 Identify and assess risk and protective factors
 Screen and identify individuals and groups at risk
 Develop and evaluate interventions to reduce risk
 Translate, implement, and disseminate effective preventive 
interventions into practice
 Develop methods to support prevention research

    ODP's strategic priorities are intentionally not specific to any 
given disease because prevention research is relevant to all health 
conditions and to promoting health in everyone; NIH's Institutes and 
Centers serve as the best place for disease-specific or condition-
specific research. As a coordinating office in the Division of Program 
Coordination, Planning, and Strategic Initiatives within the NIH Office 
of the Director, ODP is best positioned to identify important research 
gaps, fostering collaborations across NIH and with federal partners, 
and promoting rigorous research practices.

Request for Information

    ODP is seeking feedback on these draft strategic priorities:
    1. Systematically monitor NIH investments in prevention research 
and the progress and results of that research.
    2. Identify prevention research areas for investment or expanded 
effort by NIH.
    3. Promote the use of the best available methods in prevention 
research and support the development of better methods.
    4. Promote collaborative prevention research projects and 
facilitate coordination of such projects across NIH and with other 
public and private entities.
    5. Advance tobacco regulatory and prevention science.
    6. Promote and coordinate prevention research that addresses health 
disparities.
    7. Improve the availability and visibility of information about 
prevention research, inform diverse audiences about the scope and 
impact of disease prevention research, and engage with ODP's partners 
to enhance and support ODP's mission.
    ODP is also seeking feedback on areas where targeted efforts by ODP 
could help accelerate prevention research.

How To Submit a Response

    All responses to this RFI must be submitted electronically on the 
RFI submission website at https://rfi.grants.nih.gov/?s=63d9edb46e8d6ea804099132.
    Responses must be received by May 22, 2023, at 11:59 p.m. ET. You 
will see an electronic confirmation acknowledging receipt of your 
response.
    Responses to this RFI are voluntary and may be submitted 
anonymously. You may voluntarily include your name and contact 
information with your response. If you choose to provide NIH with this 
information, NIH will not share your name and contact information 
outside of NIH unless required by law.
    Other than your name and contact information, please do not include 
any personally identifiable information or any information that you do 
not wish to make public. Proprietary, classified, confidential, or 
sensitive information should not be included in your response. The 
government will use the information submitted in response to this RFI 
at its discretion. Other than your name and contact information, the 
government reserves the right to use any submitted information on 
public websites; in reports; in summaries of the state of the science; 
in any possible resultant solicitation(s), grant(s), or cooperative 
agreement(s); or in the development of future funding opportunities.
    This RFI is for informational and planning purposes only and is not 
a solicitation for applications or an obligation on the part of the 
government to provide support for any ideas identified in response to 
it. Please note that the government will not pay for the preparation of 
any information submitted or for use of that information.

    Dated: April 10, 2023.
Tara A. Schwetz,
Acting Principal Deputy Director, National Institutes of Health.
[FR Doc. 2023-08044 Filed 4-14-23; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.